MedTrace Logo

Longitudinal Imaging Biomarkers of Disease Progression in DLB

NCT03582488 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2026-03-19

No results posted yet for this study

Summary

The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline.

Conditions

  • Lewy Body Disease

Interventions

DRUG

18F-Flortaucipir

Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Kejal Kantarci

    lead OTHER

Principal Investigators

  • Kejal Kantarci, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-25
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03582488 on ClinicalTrials.gov